Drug Profile
Research programme: monoclonal antibodies - Lundbeck Seattle BioPharmaceuticals Inc
Alternative Names: ALD 1613Latest Information Update: 24 Feb 2020
Price :
$50
*
At a glance
- Originator Alder Biopharmaceuticals
- Developer Lundbeck Seattle BioPharmaceuticals Inc.
- Class Monoclonal antibodies
- Mechanism of Action Corticotropin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Congenital adrenal hyperplasia; Pituitary ACTH hypersecretion